8-K current report · filed Nov 9, 2026

MBX Biosciences, Inc. (MBX) 8-K Current Report: November 9, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2MBX overview

Short answer

MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results announced for quarter ended September 30, 2026.

MBX Biosciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging as of November 9, 2026
  • Presentation may contain material pipeline, clinical, financing, or strategic updates
  • Investors should review Exhibit 99.2 for the substantive disclosures beyond the filing notice

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $62.4M, or $1.29 per share, versus $21.6M and $0.63 in Q3 2025
  • R&D expense $32.0M, up from $19.3M, reflecting Phase 3 canvuparatide trial startup and obesity programs
  • G&A expense $34.3M, including $20.8M in stock compensation tied to the former CEO’s award modification
  • Cash and investments $481.6M after $97.6M ATM proceeds, with projected funding into 2029
  • Pivotal Phase 3 canvuparatide trial underway, while MBX 4291 12-week data remain targeted for Q4 2026

Item EX-99.2 · Exhibit EX-99.2

  • November 2026 presentation highlights $481.6M in cash, expected to fund operations into 2029
  • Canvuparatide Phase 3 trial ongoing for hypoparathyroidism, with 26-week placebo-controlled treatment and 78-week open-label extension
  • MBX 4291 12-week multiple-ascending-dose results anticipated in Q4 2026, a key validation point for monthly obesity dosing
  • MBX 4291 preliminary data showed 7% mean weight loss at 8 weeks, with 1 of 8 subjects reporting gastrointestinal events
  • MBX retains global commercial rights, preserving potential upside while retaining development and commercialization responsibility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MBX Biosciences, Inc. 8-K filings

Get the next MBX 8-K as it lands

Follow MBX for push alerts, or ask the research agent what this filing means.